Abstract:Background: LINC00173 had been reported as a cisplatin (cis-diamminedichloroplatinum, DDP) chemotherapy-resistant inducer in small-cell lung cancer (SCLC) and lung squamous cell carcinoma (LUSC). This study aimed to display reverse data for LINC00173 as a DDP chemosensitivity-inducing factor in lung adenocarcinoma (LUAD). Methods: LINC00173 was screened from the Gene Expression Omnibus database (GSE43493). The expression level of LINC00173 in LUAD tissues and cell lines was detected using in situ hybridization and quantitative reverse transcription-polymerase chain reaction. Colony formation, cell viability, half-maximal inhibitory concentration, flow cytometry, and xenograft mouse model were used to evaluate the role of LINC00173 in the chemosensitivity of LUAD to DDP. The mechanism of LINC00173 in DDP resistance by mediating miR-1275/PROCA1/ZFP36L2 axis to impair BCL2 mRNA stability was applied, and co-immunoprecipitation, chromatin immunoprecipitation, RNA antisense purification, RNA immunoprecipitation, and luciferase reporter assays were performed. Results: LINC00173 downregulation in patients with DDP-resistant LUAD was correlated with poor prognosis. Further, LINC00173 expression was significantly reduced in DDP-resistant LUAD cells and DDP-treated human LUAD tissues. Suppressed LINC00173 expression in LUAD cells enhanced DDP chemoresistance in vivo and in vitro, while restored LINC00173 expression in DDP-resistant LUAD cells markedly regained chemosensitivity to DDP. Mechanistically, DDP-resistant LUAD cells activated PI3K/AKT signal and further elevated the c-Myc expression. The c-Myc, as an oncogenic transcriptional factor, bound to the promoter of LINC00173 and suppressed its expression. The reduced LINC00173 expression attenuated the adsorption of oncogenic miR-1275, downregulating the expression of miR-1275 target gene PROCA1. PROCA1 played a potential tumor-suppressive role inducing cell apoptosis and DDP chemosensitivity via recruiting ZFP36L2 to bind to the 3' untranslated region of BCL2, reducing the stability of BCL2 mRNA and thus activating the apoptotic signal. Conclusions: This study demonstrated a novel and critical role of LINC00173. It was transcriptionally repressed by DDP-activated PI3K/AKT/c-Myc signal in LUAD, promoting DDP-acquired chemotherapeutic resistance by regulating miR-1275 to suppress PROCA1/ZFP36L2-induced BCL2 degradation, which led to apoptotic signal reduction. These data were not consistent with the previously described role of LINC00173 in SCLC or LUSC, which suggested that LINC00173 could play fine-tuned DDP resistance roles in different pathological subtypes of lung cancer. This study demonstrated that the diminished expression of LINC00173 might serve as an indicator of DDP-acquired resistance in LUAD.

Knockdown of BCL2L12 leads to cisplatin resistance in MDA-MB-231 breast cancer cells.

Chemoresistance is Associated with Overexpression of HAX-1, Inhibition of Which Resensitizes Drug-Resistant Breast Cancer Cells to Chemotherapy.

Cisplatin Induces Apoptosis of Hepatocellular Carcinoma LM3 Cells Via Down-Regulation of XIAP.

Knockdown of ZBTB11 Impedes R‐loop Elimination and Increases the Sensitivity to Cisplatin by Inhibiting DDX1 Transcription in Bladder Cancer

Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis

Bcl-2 Small Interfering RNA Sensitizes Cisplatin-resistant Human Lung Adenocarcinoma A549/DDP Cell to Cisplatin and Diallyl Disulfide

ABT737 Reverses Cisplatin Resistance by Regulating ER-mitochondria Ca2+ Signal Transduction in Human Ovarian Cancer Cells.

BCL2L12A localizes to the cell nucleus and induces growth inhibition through G2/M arrest in CHO cells

KLF12 Interacts with TRIM27 to affect Cisplatin Resistance and Cancer Metastasis in Esophageal Squamous Cell Carcinoma by regulating L1CAM Expression

Bcl-XL Small Interfering RNA Sensitizes Cisplatin-resistant Human Lung Adenocarcinoma Cells

Knock-down of NDRG2 Sensitizes Cervical Cancer Hela Cells to Cisplatin Through Suppressing Bcl-2 Expression.

CXCL12 suppresses cisplatin-induced apoptosis through activation of JAK2/STAT3 signaling in human non-small-cell lung cancer cells.

The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer

Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma

MiR-192 Confers Cisplatin Resistance by Targeting Bim in Lung Cancer

CXCL12 Suppresses Cisplatin-Induced Apoptosis Through Activation of JAK2/STAT3 Signaling in Human Non-Small-cell Lung Cancer Cells

Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin

Beclin1 Enhances Cisplatin-Induced Apoptosis Via Bcl-2-modulated Autophagy in Laryngeal Carcinoma Cells Hep-2.

WDHD1 Leads to Cisplatin Resistance by Promoting MAPRE2 Ubiquitination in Lung Adenocarcinoma

MCL-1 is the Key Target of Adjuvant Chemotherapy to Reverse the Cisplatin-Resistance in NSCLC.

Downregulation of BUBR1 regulates the proliferation and cell cycle of breast cancer cells and increases the sensitivity of cells to cisplatin